Light it Up: Glowing Sensors for Personalized Pancreatic Cancer Treatment

Karishma Kailass, Alexandra F. Tassielli, Ruifan Dai, Francisca Beato, Bhaswati Sarcar, Jennifer Permuth, Margaret Park, Jason B. Fleming, Andrew A. Beharry; Ratiometric Fluorescent Chemosensing for Predicting Response to Irinotecan-Based Therapies in Pancreatic Ductal Adenocarcinoma. ACS Sens. 22 May 2026; 11 (5): 3772–3781.

Pancreatic ductal adenocarcinoma, or PDAC is the most common and aggressive form of pancreatic cancer, accounting for roughly 90% of all pancreatic cancer cases. It has no early symptoms, so it’s often diagnosed in the later stages once it has spread to other parts of the body. PDAC has a poor outlook upon diagnosis and has a very low survival rate; 12 – 13% of diagnosed individuals live for 5 years post-diagnosis. Treatment is further limited because some tumours resist chemotherapy or develop resistance. The first-line treatment is a cocktail of drugs called FOLFIRINOX. One of the drugs in this cocktail enters the body in its unactivated form, and needs a specific enzyme, CES2, to change it into its active, cancer-killing form. The problem: some tumours have low levels of CES2, meaning that our drug cannot be activated into its cancer-killing form. If that drug can’t be activated, then the entire chemotherapy cocktail becomes ineffective, exposing patients to the harsh side effects.

Researchers looked at a specialized glowing sensor, Benz-AP to measure the activity of the really important enzyme, CES2 inside cancer cells. The sensor normally glows yellow, but in the presence of CES2, red light is visible. This change in colour is because CES2 chops the sensor into pieces and during the process, releases a compound that glows red. A brighter red signal indicates higher CES2 activity . Before this method, measuring the activity of CES2 was slow, labour-intensive, and sometimes led to destruction of cells. In comparison, Benz-AP is quicker, doesn’t require much, and results are delivered within hours using a small biopsy sample. This is one more step in humanity’s battle with PDAC; using Benz-AP, doctors can now test their patient’s tumours before starting treatment; leading to personalized treatments and avoiding toxic drugs that may not work.

Image by envandrare from Pixabay

Authors

Leave a Reply